A role for C5 and C5a-ase in the acute neutrophil response to group B streptococcal infections

Journal of Infectious Diseases

Volumn 175, Issue 4, 1997, Pages 847-855

  Bohnsack, John F ^a   Widjaja, Kartika ^b   Ghazizadeh, Saied ^b   Rubens, Craig E ^b   Hillyard, David R ^b   Parker, Charles J ^b   Albertine, Kurt H ^b   Hill, Harry R ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5; PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; MALE; MOUSE; MUTAGENESIS; NEUTROPHIL; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION;

EID: 0030901174     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513981     Document Type: Article

References (31)

1. Hill HR. Group B streptococcal infections. In: Holmes KK, Mardh PA, Sparling PF, eds. Sexually transmitted diseases. McGraw Hill: New York, 1990:851-61.
2. Quirante J, Ceballos R, Cassady G. Group B β-hemolytic streptococcal infection in the newborn. Am J Dis Child, 1974;128:659-65.
3. Hemming VG, McCloskey DW, Hill HR. Pneumonia in the neonate associated with group B streptococcal septicemia. Am J Dis Child 1976;130: 1231-3.
4. Hill HR. Biochemical, structural, and functional abnormalities of polymorphonuclear leukocytes in the neonate. Pediatr Res 1987; 22:375-82.
5. Edwards ME, Kasper DL, Jennings HJ, Baker CJ, Nicholson-Weller A. Capsular sialic acid prevents activation of the alternative pathway by type III group B streptococci. J Immunol 1982;128:1278-83.
6. Anderson DC, Hughes BJ, Edwards MS, Buffone GJ, Baker CJ. Impaired chemotaxigenesis by type III group B streptococci in neonatal sera: relationship to diminished concentration of specific anticapsular antibody and abnormalities of serum complement. Pediatr Res 1983;17: 496-502.
7. Hugli TE. Structure and function of the anaphylatoxins. Springer Semin Immunopathol 1984;7:193-219.
8. Fernandez HN, Henson PM, Otani A, Hugli TE. Chemotactic response to human C3a and C5a anaphylatoxins. J Immunol 1978;120:109-15.
9. Hill HR, Bohnsack JF, Morris EZ, et al. Group B streptococci inhibit the chemotactic activity of the fifth component of complement. J Immunol 1988;141:3551-6.
10. Bohnsack JF, Mollison KW, Buko AM, Ashworth JW, Hill HR. Group B streptococci inactivate complement component C5a by enzymic cleavage at the C-terminus. Biochem J 1991;273:635-40.
11. Bohnsack JF, Chang J, Hill HR. Restricted ability of group B streptococcal C5a-ase to inactivate C5a prepared from different animal species. Infect Immun 1993;61:1421-6.
12. Larsen GL, Mitchell BC, Harper TB, Henson PM. The pulmonary response of C5 sufficient and deficient mice to Pseudomonas aeruginosa. Am Rev Respir Dis 1982;126:306-11.
13. Toews GB, Vial WC. The role of C5 in polymorphonuclear leukocyte recruitment in response to Streptococcus pneumoniae. Am Rev Respir Dis 1984;129:82-6.
14. Verghese A, Berro E, Berro J, Franzus BW. Pulmonary clearance and phagocytic cell response in a murine model of Branhamella catarrhalis infection. J Infect Dis 1990;162:1189-92.
15. Rubens CE, Heggen LM. Tn916DE: a Tn916 derivative expressing erythromycin resistance. Plasmid 1988;20:137-42.
16. Rubens CE, Wessels MR, Heggen LM, Kasper DL. Transposon mutagenesis of group B streptococci type III capsular polysaccharide: correlation of capsule expression with virulence. Proc Natl Acad Sci USA 1987; 84:7208-12.
17. Chmouryguina I, Suvorov A, Ferrieri P, Cleary PP. Conservation of the C5a peptidase genes in group A and group B streptococci. Infect Immun 1996;64:2387-90.
18. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 1st ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
19. Wetsel RA, Fleischer DT, Haviland DL. Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5′-exon. J Biol Chem 1990;265:2435-40.
20. Basta M, Hammer CH. A rapid FPLC method for purification of the third component of human and guinea pig complement. J Immunol Methods 1991;142:39-44.
21. Parrish DA, Mitchell BC, Henson PM, Larsen GL. Pulmonary response of fifth component of complement-sufficient and -deficient mice to hyperoxia. J Clin Invest 1984;74:956-65.
22. Rothstein JL, Lint TF, Schreiber H. Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5). J Exp Med 1988;168:2007-21.
23. Barton PA, Warren JS. Complement component C5 modulates the systemic tumor necrosis factor response in murine endotoxic shock. Infect Immun 1993;61:1474-81.
24. Orr FW, Varani J, Kretzer DL, Senior RM, Ward PA. Digestion of the fifth component of complement by leukocyte enzymes. Sequential generation of chemotactic activities for leukocytes and tumor cells. Am J Pathol 1979;94:75-84.
25. Wexler DE, Nelson RC, Cleary PP. Human neutrophil chemotactic response to group A streptococci: bacteria-mediated interference with complement-derived chemotactic factors. Infect Immun 1983;39:239-46.
26. Cleary PP, Handley J, Suvorov AN, Podbielski A, Ferrieri P. Similarity between the group B and A streptococcal C5a peptidase genes. Infect Immun 1992;60:4239-43.
27. Ji Y, McLandsborough L, Kondagunta A, Cleary PP. C5a-peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect Immun 1996;64:503-9.
28. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv Immunol 1994;55: 97-179.
29. 4 and interleukin-8 from human monocytes: neonates exhibit a diminished response. J Infect Dis 1995;172:420-6.
30. Zilow G, Zilow EP, Burger R, Linderkamp O. Complement activation in newborn infants with early onset infection. Pediatr Res 1993;34: 199-203.
31. Schibler KR, Trautman MS, Liechty KW, White WL, Rothstein G, Christensen RD. Diminished transcription of interleukin-8 by monocytes from preterm infants. J Leukoc Biol 1993;53:399-403.